ClinicalTrials.gg
WithdrawnNCT06095986Updated Jun 12, 2025

A Study Evaluating the Safety, Tolerability, and Efficacy of Aramchol Meglumine in Primary Sclerosing Cholangitis

A Phase 2 interventional study of Aramchol meglumine in Primary Sclerosing Cholangitis, sponsored by Galmed Pharmaceuticals Ltd. Withdrawn at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-12.

Sponsored by Galmed Pharmaceuticals Ltd · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Operational and clinical reasons

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 75 studies in Cholangitis, Sclerosing with a site in United States — 19 open to participants now, 22 under way, 2 of them phase 3. Cholangitis, Sclerosing · United States.

Enrollment
55th of 57
0 · median 27
Started
2025
with 2 others
Phase 2
26 of 75
6 open now
Registered
66th of 75
by date

Among the 75 studies in Cholangitis, Sclerosing with a site in United States, this one is the 55th largest by enrollment of the 57 interventional ones that give a count, is one of 3 that started in 2025, is one of 26 in phase 2, and was the 66th registered.

Cholangitis, Sclerosing

150 studies on the registry are indexed under Cholangitis, Sclerosing; 40 are open to participants now.

Browse Cholangitis, Sclerosing studies →

Open to participants now

19 of the 75 studies in Cholangitis, Sclerosing with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Cholangitis, Sclerosing studies recruiting now, 12 (40%) set no upper age limit and 13 (43%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Cholangitis, Sclerosing with a site in United States, or all of them as a file.
02

Study summary

The objectives of this study is to Evaluate the Safety, Tolerability, and Efficacy of Aramchol Meglumine in Patients with Primary Sclerosing Cholangitis

Read the detailed description

The objectives of this study are to:

  • Establish the safety and tolerability of once daily (QD) Aramchol meglumine in patients with PSC
  • Examine whether once daily (QD) Aramchol meglumine has any effect on serum alkaline phosphatase
  • Provide a comprehensive readout of clinical efficacy following once daily (QD) Aramchol meglumine administration
03

Conditions studied

  • Primary Sclerosing Cholangitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female age 18 years and above (inclusive at first screening visit)
  2. Established diagnosis of large duct PSC based on abnormal cholangiography as assessed by magnetic resonance cholangiopancreatography (MRCP) or Endoscopic retrograde cholangiopancreatography (ERCP)
  3. Alkaline phosphatase > 150 IU/l
  4. Stable inflammatory bowel disease therapy > 3months for IBD patients
  5. If receiving treatment with Ursodeoxycholic acid (UDCA; ursodiol), therapy is at a dose of \<20 mg/kg/day, has been stable for at least 6 months before screening
  6. Ability to understand the nature of the study and to sign a written form (ICF)

Exclusion criteria

Exclusion Criteria:

  1. Other causes of liver disease, including secondary sclerosing cholangitis or viral, metabolic, or alcoholic liver disease, as assessed clinically
  2. Active Crohn's disease (CDAI > 40) or ulcerative colitis (Mayo IBD score > 4) or active non-hemorrhoidal rectal bleeding
  3. Small bowel resection > 100 cm
  4. Cirrhosis (clinically evident or by )
  5. Prior hepatic decompensation event
  6. Recent (\< 6 weeks) acute cholangitis or hospitalization for PSC or IBD
  7. Bleeding diathesis or other for liver biopsy
  8. Known GI or hepatobiliary
  9. Prior liver transplantation
  10. Prior exposure to study drug
  11. Active untreated viral hepatitis or other concomitant liver disease
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    PSC patients administered with Aramchol meglumine

    Adult subjects with clinically diagnosed PSC that are administered with Aramchol meglumine

    Drug: Aramchol meglumine

  • Placebo comparator
    PSC patients administered with placebo

    Adult subjects with clinically diagnosed PSC that are administered with matching placebo

    Drug: Aramchol meglumine

Interventions

  • DrugAramchol meglumine

    Aramchol meglumine is derived from a weak acid (Aramchol) and an amino-sugar (meglumine)

06

What researchers measure

Primary outcomes

  1. Change from Baseline in serum alkaline phosphatase (ALP)

    The change from Baseline to Week 48 in ALP levels

    Time frame: 48 weeks

Secondary outcomes

  1. Change from Baseline in hepatobiliary fibrosis using the Nakanuma staging scale

    Change from Baseline to Week 48 in liver histology using the Nakanuma stage classification. A score of 0 is classified as stage 1 (no or minimal disease progression), while 1 score 5 or 6 is classified as stage 4 (advanced disease progression).

    Time frame: 48 weeks

  2. Change from Baseline in Enhanced liver fibrosis (ELF)

    Change from Baseline to Week 48 in Enhanced liver fibrosis (ELF) test. Score below 7.7 indicate no to mild fibrosis, and score higher than 11.3 indicate cirrhosis.

    Time frame: 48 weeks

  3. Change from Baseline in MRCP

    Change from Baseline to Week 48 in magnetic resonance cholangiopancreatography (MRCP)

    Time frame: 48 weeks

  4. Change from Baseline in quantitative liver function using Gadoxetate clearance

    Change from Baseline to Week 48 in quantitative liver function using Gadoxetate clearance

    Time frame: 48 weeks

  5. Change from Baseline in 5D-itch scale

    Change from Baseline to Week 48 in the 5 dimension itch scale (5d-itch scale) measuring pruritus (the 5 dimensions are degree, duration, direction, disability and distribution). Higher degree mean worse outcome \<8 on rating scale mean no pruritus, and \>22 on rating scale indicate severe pruritus

    Time frame: 48 weeks

  6. Change from Baseline to Week 48 in Patient-Reported Outcomes Measurement Information System (PROMIS)-19 score

    Change from Baseline to Week 48 in the Patient-Reported Outcomes Measurement Information System (PROMIS)-19 questionnaire score. The average score for Physical Function is 50, with a score of 40 considered below average and a score of 60 considered above average

    Time frame: 48 weeks

  7. Change from Baseline in the Mayo IBD symptom severity score

    Change from Baseline to Week 48 in the Mayo Inflammatory bowel disease (IBD) symptom severity score. A score of 3 to 5 points indicates mildly active disease and a score of 11 to 12 points indicates severely active bowel disease

    Time frame: 48 weeks

  8. Change from Baseline in the revised Mayo risk score (rMRS)

    Change from Baseline to Week 48 in the revised Mayo risk score (rMRS). The score provide the estimated probability of survival (%) based on age, bilirubin, AST, and history of bleeding

    Time frame: 48 weeks

  9. Change from Baseline in the UK-PSC score

    Change from Baseline to Week 48 in the united kingdom primary sclerosing cholangitis (UK-PSC) score. The score provide the estimated probability of survival (%) based on age, bilirubin, albumin, platelets, hemoglobin and ALP

    Time frame: 48 weeks

  10. Change from Baseline in the PSC risk estimate tool (PREsTo)

    Change from Baseline to Week 48 in the PSC risk estimate tool (PREsTo). The tool consists of bilirubin, albumin, ALP, platelets, AST, hemoglobin, sodium, patient age and the number of years since PSC was diagnosed, and it predicts short-term and long-term need for liver transplantation or death.

    Time frame: 48 weeks

07

Study locations

1 site
  • The Sanyal Institute for Liver Disease &amp; Metabolic Health at VCU
    Richmond, Virginia 23284, United States
08

References and documents

Individual participant data

Plan to share: Yes — Share the study protocol and SAP

Supporting information: Study protocol, Statistical analysis plan

Time frame: Study completion

Access criteria: Any person with access to ClinicalTrials.gov

Data sharing details ↗ · galmedpharma.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2025; primary completion for Sep 2026, 15 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2023
First posted
Oct 23, 2023
StartEst.
Jun 2025
Primary completionEst.
Sep 2026
CompletionEst.
Dec 2027
Last update
Jun 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06095986
Lead sponsor
Galmed Pharmaceuticals Ltd
Responsible party
Sponsor
First posted
Oct 23, 2023
Start date
Jun 2025 (estimated)
Primary completion
Sep 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jun 12, 2025

Study contacts

Arun Sanyal, MD
principal investigator · The Sanyal Institute for Liver Disease & Metabolic Health at VCU

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion